APPROVECAMYZYOS (MAVACAMTEN) NEW APPROACH IN CONGESTIVE HEART FAILURE: A REVIEW
Creators
- 1. Arya College of Pharmacy, Kukas, Jaipur, Rajasthan, India
Description
FDA has approvecamyzyos (mavacamten) capsule. The main aim of camyzyos drug to treat
obstructive hypertrophic cardiomyopathy (oHCM). Camyzyos, first and only FDA approved
drug that inhibit the myosin inhibitor. camyzyos available in various range like, 2.5mg, 5mg,
10mg, 15mg, capsules for the treatment of adults with symptomatic obstructive hypertrophic
cardiomyopathy. Mavacamten is a targeted inhibitor of cardiac myosin that reduces the
number of myosin actin cross bridge and decreases contractility. Mavacamten is selective
allosteric modulator of cardiac myosin ATPase. Currently available pharmacological
symptoms of oHCM are not disease specific. oHCM is a monogenic C.V disorder that often
goes undiagnosed and can provide a variety of symptoms like, shortness of birth, it causes
sudden cardiac death. oHCM mainly causes due to excessive contraction of the left ventricle.
In patients, camyzyos decrease the pressure gradient contributing to obstruction of VLOT.
Mavacamten trail show that mavacamten was superior to placebo at improving exercise
capacity of health status. Some patients who take placebo HCM feel better, and some other
patients develop side effects, but in the case of mavacamten try to give best pharmacological
action, rarely produce side effect.
Abstract (English)
FDA has approvecamyzyos (mavacamten) capsule. The main aim of camyzyos drug to treat
obstructive hypertrophic cardiomyopathy (oHCM). Camyzyos, first and only FDA approved
drug that inhibit the myosin inhibitor. camyzyos available in various range like, 2.5mg, 5mg,
10mg, 15mg, capsules for the treatment of adults with symptomatic obstructive hypertrophic
cardiomyopathy. Mavacamten is a targeted inhibitor of cardiac myosin that reduces the
number of myosin actin cross bridge and decreases contractility. Mavacamten is selective
allosteric modulator of cardiac myosin ATPase. Currently available pharmacological
symptoms of oHCM are not disease specific. oHCM is a monogenic C.V disorder that often
goes undiagnosed and can provide a variety of symptoms like, shortness of birth, it causes
sudden cardiac death. oHCM mainly causes due to excessive contraction of the left ventricle.
In patients, camyzyos decrease the pressure gradient contributing to obstruction of VLOT.
Mavacamten trail show that mavacamten was superior to placebo at improving exercise
capacity of health status. Some patients who take placebo HCM feel better, and some other
patients develop side effects, but in the case of mavacamten try to give best pharmacological
action, rarely produce side effect.
Files
IJCPR,Vol14,Issue2,Article4.pdf
Files
(508.7 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:5d26d1f950b54ceb55d1662887b75a27
|
508.7 kB | Preview Download |
Additional details
Dates
- Accepted
-
2020-03-31